姜国平

[摘要] 目的 分析他克莫司联合利妥昔单抗治疗系统性红斑狼疮的治疗效果。方法 便利选择2018年4月—2019年7月之间该院收治的系统性红斑狼疮患者92例，秉持平均分配的原则将其随机分为两组，各46例。对照组病患使用他克莫司进行治疗，观察组患者应用他克莫司联合利妥昔单抗进行治疗，观察分析两组患者的治疗效果。结果 对照组患者治疗显效14例，有效19例，总有效率为71.74%;观察组患者治疗显效18例，有效24例，总有效率为91.30%，经统计差异有统计学意义（χ2=5.845，P=0.030<0.05）。观察组不良反应发生率为10.87%;对照组不良反应发生率为32.61%，差异有统计学意义（χ2=6.389，P=0.021<0.05）。结论 他克莫司联合利妥昔单抗治疗系统性红斑狼疮，效果更好，不良反应发生率低，值得推广应用。

[关键词] 他克莫司;利妥昔单抗;系统性红斑狼疮

[Abstract] Objective To analyze the therapeutic effect of tacrolimus combined with rituximab on systemic lupus erythematosus. Methods A total of 92 patients with systemic lupus erythematosus treated in the hospital between April 2018 and July 2019 were conveniently selected. They were randomly divided into two groups based on the principle of equal distribution， with 46 patients each. Patients in the control group were treated with tacrolimus， patients in the observation group were treated with tacrolimus in combination with rituximab， and the therapeutic effects of the two groups of patients were observed and analyzed. Results In the control group， 14 cases were markedly effective， 19 cases were effective， and the total effective rate was 71.74%. In the observation group， 18 cases were significantly effective， 24 cases were effective， and the total effective rate was 91.30%. According to statistics， the difference was statistically significant （χ2=5.845， P=0.030 <0.05）. The incidence of adverse reactions in the observation group was 10.87%; the incidence of adverse reactions in the control group was 32.61%，  the difference was statistically significant（χ2=6.389， P=0.021 <0.05）， which were significantly different. Conclusion Tacrolimus combined with rituximab in the treatment of systemic lupus erythematosus is more effective and has a lower incidence of adverse reactions， which is worthy of popularization and application.

[Key words] Tacrolimus; Rituximab; Systemic lupus erythematosus

系統性红斑狼疮是一种风湿性免疫疾病，累及患者多个器官，严重影响患者生活质量[1]。目前临床上治疗系统性红斑狼疮主要使用糖皮质激素、免疫抑制剂等药物，随着医疗技术的进步，治疗系统性红斑狼疮的药物的不断改进，激素以及免疫抑制剂类药物的使用更加规范化，患者的生存期不断延长[2]。不过激素以及免疫抑制剂类药物在发挥治疗作用的同时导致的不良反应不应受到忽视，必须重视药物产生的不良反应，防止带来严重后果。有研究表明[3]，他克莫司和小剂量的利妥昔单抗用于治疗系统性红斑狼疮疗效较好，安全性较高。为探究他克莫司联合利妥昔单抗治疗系统性红斑狼疮的治疗效果，该文便利选择2018年4月—2019年7月之间该院收治的系统性红斑狼疮患者92例进行试验观察，取得良好结果，现报道如下。

1  资料与方法

1.1  一般资料

便利选择该院收治的系统性红斑狼疮患者92例，将其随机分为两组，各46例。……